Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

Partner | Cancer Centers | <b>Huntsman Cancer Institute at the University of Utah </b>

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator at Huntsman Cancer Institute, discusses the tolerability of apalutamide (Erleada) in metastatic castration-sensitive prostate cancer (mCSPC).

In September 2019, the FDA approved apalutamide for the treatment of patients with mCSPC based on interim results from the phase 3 TITAN trial. At the 2020 Genitourinary Cancers Symposium, a posthoc analysis from TITAN showed that early intensification with apalutamide may positively affect the disease trajectory for these patients who receive subsequent therapy with chemotherapy or novel hormonal agents.

Importantly, no new safety signals were noted with the agent in the updated findings, says Agarwal.

At the 2019 ESMO Congress, quality-of-life (QoL) data from the TITAN study showed that patients did not experience worsening QoL with apalutamide compared with placebo.

Identifying novel therapies that elicit significant survival benefits while maintaining QoL for patients is critical, concludes Agarwal.